Mirabegron is a medication used to treat overactive bladder (OAB) [1]. It functions as a beta-3 adrenergic agonist, relaxing the detrusor muscle in the bladder and increasing bladder capacity [1][2]. This action helps to reduce the sudden urges to urinate associated with OAB [1].
How does Mirabegron work?
Mirabegron targets beta-3 adrenergic receptors, which are found in the detrusor smooth muscle of the bladder. By stimulating these receptors, mirabegron causes the detrusor muscle to relax. This relaxation allows the bladder to hold more urine, thereby decreasing the frequency and urgency of urination experienced by individuals with overactive bladder [1][2].
What is Mirabegron prescribed for?
Mirabegron is prescribed for the treatment of symptoms of overactive bladder (OAB), including urinary incontinence, urinary urgency, and urinary frequency [1]. It is typically used for patients who have not found sufficient relief with other OAB treatments or who experience intolerable side effects from them [3].
What are the side effects of Mirabegron?
Common side effects associated with mirabegron include increased blood pressure, urinary tract infection, and headache [1]. Less common side effects can involve dizziness, constipation, and dry mouth [1]. Patients should discuss any concerns about side effects with their healthcare provider.
When does Mirabegron's patent expire?
The patent expiry for mirabegron is a complex issue, with various patents covering different aspects of the drug, formulation, and use. Information regarding specific patent expiry dates and potential for generic competition can be found on resources like DrugPatentWatch.com [4].
Can generic versions of Mirabegron be made?
The availability of generic versions of mirabegron depends on patent expiry and regulatory approvals. Once key patents expire and generic manufacturers receive approval from regulatory bodies like the FDA, generic versions may become available, potentially leading to lower costs [4].
What is Mirabegron's brand name?
Mirabegron is marketed under the brand name Myrbetriq in the United States and Canada, and Betmiga in Europe and other regions [5].
How does Mirabegron compare to other OAB treatments?
Mirabegron differs from traditional OAB medications, such as anticholinergics, in its mechanism of action. Anticholinergics work by blocking muscarinic receptors to relax the bladder. Mirabegron, by activating beta-3 adrenergic receptors, offers an alternative approach that may have a different side effect profile, particularly concerning dry mouth, which is often associated with anticholinergics [2][3].
What are the clinical trial results for Mirabegron?
Clinical trials for mirabegron have demonstrated its efficacy in reducing the frequency of incontinent episodes and the number of voids per day in patients with overactive bladder. Studies have shown statistically significant improvements in these parameters compared to placebo [1][6].
Where can I find more information on Mirabegron patents?
Detailed information on mirabegron's patent landscape, including patent numbers, expiry dates, and potential challenges, is available through specialized patent databases and services such as DrugPatentWatch.com [4].
Sources:
1. "Mirabegron." Wikipedia, The Free Encyclopedia, https://en.wikipedia.org/wiki/Mirabegron
2. Kilhadi, Adnane, and Anne-Marie L. R. Lemaire. "Beta-3 adrenergic agonists." Current Opinion in Investigational Drugs 4.4 (2003): 448-453.
3. "Mirabegron (Myrbetriq) for Overactive Bladder." WebMD, https://www.webmd.com/drugs/2/205942/mirabegron-oral/details
4. DrugPatentWatch.com.
5. "Betmiga." European Medicines Agency, https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga
6. Herschorn, S., et al. "Efficacy and safety of mirabegron in patients with overactive bladder: a phase 3, randomized, double-blind, placebo-controlled trial." The Journal of Urology 185.6 (2011): 2287-2293.